P Schoenfeld Asset Management LP bought a new stake in Kenvue Inc. (NYSE:KVUE – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 128,200 shares of the company’s stock, valued at approximately $2,211,000. Kenvue comprises about 0.8% of P Schoenfeld Asset Management LP’s investment portfolio, making the stock its 24th biggest holding.
Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Kenvue by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock worth $4,052,913,000 after buying an additional 1,604,040 shares during the last quarter. State Street Corp increased its stake in shares of Kenvue by 3.5% during the 4th quarter. State Street Corp now owns 118,865,134 shares of the company’s stock valued at $2,050,424,000 after acquiring an additional 4,063,257 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Kenvue by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock worth $856,778,000 after acquiring an additional 371,322 shares during the period. Norges Bank acquired a new stake in shares of Kenvue in the fourth quarter worth approximately $756,862,000. Finally, American Century Companies Inc. boosted its position in shares of Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock worth $601,267,000 after acquiring an additional 6,781,640 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Kenvue Stock Down 0.1%
KVUE opened at $18.13 on Monday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The firm has a 50 day moving average price of $17.43 and a 200 day moving average price of $17.54. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The company has a market cap of $34.80 billion, a PE ratio of 21.32, a price-to-earnings-growth ratio of 1.38 and a beta of 0.54.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.6%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.
Insiders Place Their Bets
In related news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.59% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Canaccord Genuity Group upped their price target on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Barclays decreased their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. UBS Group lowered their price objective on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Citigroup dropped their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Finally, Weiss Ratings lowered Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $19.33.
Read Our Latest Report on Kenvue
Kenvue Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Read More
- Five stocks we like better than Kenvue
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}